(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of -25.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.
Vir Biotechnology's revenue in 2026 is $303,227,000.On average, 11 Wall Street analysts forecast VIR's revenue for 2026 to be $42,119,544,106, with the lowest VIR revenue forecast at $31,841,366,817, and the highest VIR revenue forecast at $57,019,009,208. On average, 10 Wall Street analysts forecast VIR's revenue for 2027 to be $17,190,649,173, with the lowest VIR revenue forecast at $10,953,179,745, and the highest VIR revenue forecast at $27,485,748,058.
In 2028, VIR is forecast to generate $27,355,451,770 in revenue, with the lowest revenue forecast at $9,384,886,247 and the highest revenue forecast at $53,907,127,740.